A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus FOLFOX ± Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study).
Feng-Hua WangMing-Ming HeJian XiaoYan-Qiao ZhangXiang-Lin YuanWei-Jia FangYan ZhangWei WangXiao-Hua HuZhi-Gang MaYi-Chen YaoZhi-Xiang ZhuangYingying ShiJie-Er YingYing YuanQing-Feng ZouZeng Qing GuoXiang-Yuan WuYing JinZong-Jiong MaiZhi-Qiang WangHong QiuYing GuoSi-Mei ShiShuang-Zhen ChenHui-Yan LuoDong-Sheng ZhangFeng-Hua WangYu-Hong LiRui-Hua XuPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
High-dose vitamin C plus chemotherapy failed to show superior PFS compared with chemotherapy in patients with mCRC as first-line treatment but may be beneficial in patients with mCRC harboring RAS mutation.